Short answer
Gilead Sciences (GILD) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Gilead reported financial results for quarter ended June 30, 2026.
Gilead Sciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Gilead reported financial results for quarter ended June 30, 2026
- Full operating metrics and GAAP-to-non-GAAP reconciliations are in Exhibit 99.1
- Investors should prioritize GAAP results, using non-GAAP measures as supplemental performance indicators
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue rose 10% to $7.8B, led by HIV sales up 12% to $5.7B and Trodelvy sales up 26% to $457M
- Biktarvy grew 7% to $3.8B and Descovy surged 48% to $967M, reinforcing HIV portfolio momentum
- GAAP EPS $(8.45) versus $1.56, driven by $11.2B acquired IPR&D and $1.75B IPR&D impairment
- Cash declined to $3.2B from $10.6B after $11.3B acquisition outflows, $2.8B debt repayments and $2.1B dividends
- 2026 product-sales guidance increased to $30.1B-$30.4B, while non-GAAP loss guidance improved to $(0.65)-$(0.30) per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gilead Sciences 8-K filings
Get the next GILD 8-K as it lands
Follow GILD for push alerts, or ask the research agent what this filing means.